Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1958 2
1959 1
1960 1
1962 1
1963 1
1965 3
1966 4
1967 3
1968 2
1969 1
1970 2
1973 2
1974 3
1976 3
1977 1
1978 4
1979 2
1980 12
1981 1
1982 6
1983 7
1984 7
1985 15
1986 8
1987 10
1988 12
1989 4
1990 10
1991 4
1992 4
1993 6
1994 3
1995 3
1996 4
1997 5
1998 4
1999 4
2000 4
2001 2
2002 4
2003 4
2004 3
2005 7
2006 5
2007 8
2008 6
2009 5
2010 5
2011 15
2012 10
2013 14
2014 16
2015 8
2016 15
2017 15
2018 13
2019 19
2020 22
2021 27
2022 25
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. Among authors: watari h. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Free PMC article. Clinical Trial.
Lymphadenectomy issues in endometrial cancer.
Konno Y, Asano H, Shikama A, Aoki D, Tanikawa M, Oki A, Horie K, Mitsuhashi A, Kikuchi A, Tokunaga H, Terao Y, Satoh T, Ushijima K, Ishikawa M, Yaegashi N, Watari H. Konno Y, et al. Among authors: watari h. J Gynecol Oncol. 2021 Mar;32(2):e25. doi: 10.3802/jgo.2021.32.e25. Epub 2021 Jan 7. J Gynecol Oncol. 2021. PMID: 33470067 Free PMC article. Review.
Evaluation of five Legionella urinary antigen detection kits including new Ribotest Legionella for simultaneous detection of ribosomal protein L7/L12.
Nakamura A, Fukuda S, Kusuki M, Watari H, Shimura S, Kimura K, Nishi I, Komatsu M; Study of Bacterial Resistance in the Kinki region of japan (SBRK) group. Nakamura A, et al. Among authors: watari h. J Infect Chemother. 2021 Oct;27(10):1533-1535. doi: 10.1016/j.jiac.2021.05.019. Epub 2021 Jun 2. J Infect Chemother. 2021. PMID: 34088604
Time for enhancing government-led primary prevention of cervical cancer.
Min KJ, Suh DH, Baba T, Chen X, Kim JW, Kobayashi Y, Kwon J, Lim MC, Lee JY, Nagase S, Park JY, Tangjitgamol S, Watari H. Min KJ, et al. Among authors: watari h. J Gynecol Oncol. 2021 Jan;32(1):e12. doi: 10.3802/jgo.2021.32.e12. Epub 2020 Dec 11. J Gynecol Oncol. 2021. PMID: 33327045 Free PMC article. No abstract available.
Emerging therapeutic biomarkers in endometrial cancer.
Dong P, Kaneuchi M, Konno Y, Watari H, Sudo S, Sakuragi N. Dong P, et al. Among authors: watari h. Biomed Res Int. 2013;2013:130362. doi: 10.1155/2013/130362. Epub 2013 Jun 11. Biomed Res Int. 2013. PMID: 23819113 Free PMC article. Review.
404 results